Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today it has entered into an exclusive Named Patient Program distribution agreement for its non-opioid metastatic cancer bone pain drug, Strontium89, with Caligor Coghlan Pharma Services (CCPS) for the ex-U.S. market. Over ten million people around the world suffer from pain associated with metastatic cancer in the bone and can benefit from Strontium89. The distribution agreement provides global access to this important therapy almost immediately for a very needy patient population and the Company expects to fulfill orders within the next 30-60 days.

This Named Patient Program provides patients and physicians access to commercially approved medicines that are not available to them in their own country. These drugs must be approved in at least one country, must not have direct alternatives, and must serve a significant patient unmet need. Strontium89 meets all of these criteria.

For nearly two years, there has been limited or no availability of this vital therapy throughout the world, after GE Healthcare stopped manufacturing it in December of 2018. Q BioMed is pleased that this agreement and implementation of the Named Patient Program will ensure immediate global patient access to an important therapy for this patient population.

Caligor Coghlan Pharma Services is a company with a long history in the advancement of patient access to treatments in the medical device and pharmaceutical space. The company has full service capabilities with specific global expertise in the design, development, and delivery of compassionate use, named patient, unlicensed medicine, and early access programs for the pharmaceutical and biotechnology industry.

Strontium89 is an FDA-approved non-opioid radiopharmaceutical indicated for the treatment of painful skeletal metastases caused by cancer. In several multicenter, placebo-controlled trials in cancer patients with pain from bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo. Strontium89 is administered intravenously once every three months and for some patients can reduce or even eliminate the need for opioid analgesics. (Please see Important Safety Information and the full Prescribing Information on our website www.strontium89.com).

Denis Corin, CEO of Q BioMed, said of the partnership, “We are very happy we can enable non-U.S. physicians to prescribe a safe, effective and non-opioid treatment to their bone metastasis pain patients. Our partnership with Caligor Coghlan ensures that patients all around the world suffering from bone cancer pain can find non-opioid pain relief from this well established drug.”

Lynn Waltzman, Sr. Director Early Access Programs at CCPS, said, “CCPS is privileged to be working with Q BioMed and being a contributor in bringing something so valuable to those that need it most. Pain from advanced cancer is an area which often goes under-represented in the medical community. We have seen first hand the benefit and impact of treatments like Strontium89 to those who are suffering. Q BioMed has made it a mission to bring comfort to those who need it most and a time when pain should be the last thing they worry about.”

Q BioMed and Caligor Coghlan intend to announce further details regarding availability of Strontium89 via the Named Patient Program throughout Europe and AsiaPac regions later in July. Any queries about the program and availability can be directed to info@qbiomed.com.

About Q BioMed Inc.
Q BioMed Inc is a biotech acceleration and commercial stage company. Q BioMed is focused on licensing and acquiring undervalued biomedical assets in the healthcare sector. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support, and expansion capital needed to ensure they meet their developmental potential, enabling them to provide products to patients in need‏.

Please visit http://www.QBioMed.com and sign up for regular updates.

Media Contact Q BioMed:
Denis Corin

Investor Relations
+1(404) 995-6671

About Caligor Coghlan Pharma Services
Caligor Coghlan Pharma Services is global provider of pharma services to assist in the development to commercialization of pharmaceutical, biotechnology, and medical device assets. Services include clinical trial design, clinical and commercial packaging and labeling, IMP management and distribution, comparator and ancillary procurement, Clinical Supply Management, Early Access to Medicines services, global Regulatory consulting, commercialized product distribution, and asset acquisition planning. The company operates facilities in Bastrop, TX, USA, and Dartford, UK, and maintains a global network of depots to ensure rapid and timely delivery of therapeutics and supplies to patients and physicians globally. www.calcog.com

Media Contact:
Kerry Myers
Vice President of Commercial